New cost effective RP-HPLC method development and evaluation for quantitative estimation of Pitavastatin in pharmaceutical formulation
Ajeet Patel*, Pushpendra Soni, Neha Yadav, Lavakesh Kumar Omray
ONLINE ISSN : 2456-8244ABSTRACT
A simple, sensitive, reliable and rapid reversed-phase high-performance liquid
chromatographic (RP-HPLC) method has been developed and validated for the
determination of pitavastatin in bulk and pharmaceutical dosage form. The chromatographic
system consisted of waters (784), 515 binary Pump, data Ace with UV-Visible detector.
Separation was achieved on the thermo C18 (250 x 4.60), 5 μ particle size column in isocratic
mode at room temperature. The sample was introduced through an injector valve with a 20
μl, sample loop. 20mM KH2PO4 (pH-3.0 with OPA): Acetonitrile 20:80 (%, v/v), was used as
mobile phase with flow rate of 1 ml/min. UV detection was performed at 250 nm. A
calibration graph was plotted which showed a linearity range between5-25 μg/ml with the
correlation coefficient of 0.997. The LOD was 0.095μg/ ml, while the LOQ was 0.271
μg/ml. Validation studies revealed the method is specific, rapid, reliable and reproducible. To
study the validity of the method, recovery studies and repeatability studies were carried out
using the same optimum conditions. The system suitability studies were also calculated which
includes column efficiency, resolution, capacity factor and peak asymmetrical factor.
Therefore the proposed method is reliable, rapid, precise and selective so may be used for the
quantitative analysis of pitavastatin.
KEYWORDS
HPLC, Pitavastatin, Pharmaceutical dosage form, Method Validation
DOI
REFERENCES
1. M. Soyka, C. Schuetz, and U. Preuss,
Drugs in R & D, 3, 58–60 (2002)
2. Martindale: The Complete Drug
Reference, 35th edn, Pharmaceutical
Press, London, 2007, pp. 1234
3. Remington: The Science and Practice
of Pharmacy, 21st edn, Lippincott
Williams & Wilkins, New York, 2006,
pp. 1368
4. L. Rosa and C. John, Amer. J.
Cardiovasc. Drugs, 3, 271–281 (2003)
5. K. Kalinami, N. Takekoshi, and Y.
Saito, Cardiovasc. Drug Rev., 21, 199–
215 (2003)
6. The Merck Index, 14th edn, Merck
Research Laboratories, Division of
Merck and Co. Inc., Whitehouse
Station, NJ, 2006, pp. 1294–1295.
7. Krishna M.V. and Sankar D.G.
Adaptation of colour reactions for
spectrophotometric determination of
pitavastatin calcium in bulk drugs and
in pharmaceutical formulations. E-J.
Chem., 2007, 4, 272-278.
8. Vadia N.H., Vandana P. and Bhalara
H.N. Spectrophotometric
Determination of Cefetamet pivoxil
hydrochloride and Pitavastatin
Calcium in Tablet Dosage Form.
Indian J. Pharm. Sci., 2008, 70, 649-
651.
9. Satheesh N.K. and Baghyalakshmi J.
Determination and Quantification of
PitavastatinCalcium in Tablet Dosage
Formulation by HPTLC Method.
Anal. Lett., 2007, 40, 2625- 2632.
10. Hiral J.P., Bhanubhai N.S., Natvarlal
J.P. and Bhavesh H.P. A Simple and
Sensitive HPTLC method for
Estimation of Pitavastatin Calcium in
Tablet Dosage Form. J. Planar
Chrom., 2008, 21, 267-270.
11. Kojima J., Fujino H., Yosimura M.,
Morikawa H. and Kimata H.
Simultaneous Determination of NK-
104 and its lactone in Biological
samples by Column-switching highperformance
liquid chromatography
with Ultraviolet detection. J.
Chromatogr. B, 1999, 724, 173-180.
12. Ramakrishna N., Koteshwara M. and
Vishwottam K. Chromatography–
Mass Spectrometry Methods for the
Quantitation of Statins in Biological
samples. J. Pharm. Biomed. Anal.,
2007, 44, 379- 387.
13. Nanjappan S.K., Narayanan N.,
Jayabalan N., Narayanan S. and
Bagyalakshmi J. HPLC Determination
of Pitavastatin Calcium in
Pharmaceutical Dosage Form.
Pharma. Ana. Acta, 2011, 2, 119.
14. Hiral J.P. and Bhanubhai N.S. HPLC
Determination of Pitavastatin Calcium in Pharmaceutical Dosage. J. AOAC
Int., 2009, 92, 158-64.
15. Ojha A., Guttikar S., Vayeda C. and
Padh H. Determination of Pitavastatin
from Human Plasma. Se Pu, 2007, 25,
715-718.
16. Pawel G., Giampietro V., Daniela V.,
Francesco D., Anna G. and Jadwiga
M. Photo Stability of Pitavastatin-A
Novel HMG-CoA reductase inhibitor.
J. Pharm. Biomed. Anal., 2009, 50,
597- 601.
17. Hiral J.P. and Bhanubhai N.S. Stability
Indicating High Performance Liquid
Chromatographic Method for
Determination of Pitavastatin Calcium
In Tablet Dosage Form. Acta Chrom.,
2011, 3, 81-94.
18. Antony R.G., Pannala R.R.,
Nimmakayala S. and Jadi S.
Degradation Pathway for Pitavastatin
Calcium by Validated Stability
Indicating UPLC Method. American J.
Ana. Chem., 2010, 2, 83-90.
19. Jian W.D., Kwon B.K., Hong H.Z.,
Kwang H.L. and Jae G.S.
Determination of two HMG-CoA
reductase inhibitors, Pravastatin and
Pitavastatin, in Plasma samples using
Liquid chromatography-Tandem Mass
Spectrometry for Pharmaceutical
study. Biomed. Chrom., 2008, 22, 131-
135.
20. Lei T., Yiling H., Youhong J., Lu H.
and Yishi L. Development and
Validation of a Liquid
chromatography-Tandem Mass
Spectrometric assay for Pitavastatin
and its lactone in human plasma and
Urine. J. Chrom. B, 2008, 865, 127-
132.
21. Hua L.V., Jian G.S., Guang J.W., Xiao
Y.Z., Ying Z., Sheng H.G., Yan L. and Jie S. Determination of Pitavastatin in
Human plasma via HPLC-ESIMS/
MS. Clin. Chimica Acta, 2007, 386, 25-
30.
22. Code Q2 (R1) -Text on Validation of
Analytical Procedures: Text and
Methodology Current Step 4 version,
2005, ICH Harmonised Tripartite
Guideline.